Antipsychotics

The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

Martin Harrow's study tracing the effects of antipsychotics on 139 schizophrenia (SZ) and mood-disordered patients over 20 years, just published in Psychological Medicine, finds...

Members of the U.S. Food and Drug Administration’s Psychiatry Products division go on the defensive in a new article, responding to concerns about the agency’s approval of digital aripiprazole.

Swedish researchers find, in a study of all women giving birth in Sweden from July 1, 2005 through December 31, 2009 that those taking...

Researchers in Singapore find that antipsychotic medications are associated with changes to colonic architecture, which could result in difficult colonoscopy and increased colonoscopy-related risks....

Antipsychotics present a known risk for major side effects. A new study suggests that certain antipsychotics may present a greater risk for cardiovascular disease than others.

A systematic review published this week in the British Journal of Clinical Pharmacology found that patients taking antipsychotic drugs were at nearly twice the risk...

Study finds that 74% of patients with a psychotic disorder off antipsychotics at end of 10 years are in remission.

A new study published this month in the journal Neuron identifies the mechanism by which antipsychotic drugs can induce parkinsonism, a condition involving movement...

Three independent studies in two journals reported strong links between antipsychotics and falls and fractures.

It is very common for psychiatric patients, especially those diagnosed with schizophrenia, to be prescribed two or more psychiatric medications at once, and this...

Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.

Review of a new mixed depression guideline reveals financial bias of guideline developers and lack of evidence supporting recommendations for prescribing of antipsychotics.

A literature review found that the extensive off-label use of antipsychotic medications in nursing homes is causing many adverse effects and providing limited benefits.

Evidence-Based Mental Health reviews studies (from 1987 to 2011) of antipsychotics in people under 24 years old, finding weak evidence on comparative effectiveness of antipsychotics or...

With pharmaceutical companies pushing antipsychotics for off-label use, dementia patients are being put at risk for devastating health consequences. Research suggests safer alternatives exist—but why aren’t they being prioritized?

A new study in JAMA Neurology finds that the use of antipsychotic drugs more than doubled the risk of death in patients with Parkinson’s...

New research highlights the ethical responsibilities of clinicians in supporting patients who choose to reduce or discontinue antipsychotic medication.

Reduced usage of antipsychotics in first-episode psychosis was associated with improved executive functioning.

The US FDA has issued a new warning for the atypical antipsychotic Olanzapine, also known by the brand names Zyprexa and Symbyax. The agency...

A new review finds a lack of available guidance on how to effectively monitor adverse effects of antipsychotic drug clozapine.

New research demonstrates that children diagnosed with ADHD at younger ages are more likely than those diagnosed later to receive multiple medications within five years of their diagnosis.

A new attempt to study the neurological effects of long-term exposure to antipsychotics uses healthy volunteers on minimal doses for 15 days.

MedPageToday reports that Janssen Pharmaceuticals omitted data from a 2003 study that connected Risperdal with serious side effects. Janssen was previously sued by the FDA for marketing Risperdal for off-label uses and settled for $2.2 billion in 2013. Earlier this year, a man with autism was awarded $2.5 million after growing breasts while on Risperdal. According to MedPage, documents from this latest case reveal missing data tables from a 2003 study “designed to ferret out potential adverse effects of long-term risperidone use.” The missing tables were related to elevated prolactin levels and side effects, including gynecomastia in men.

The editor of the British Journal of Psychiatry, in a comment on Morrison et al.'s "Antipsychotics: is it Time to Introduce Patient Choice," announces...